Lightnews — Scholar-powered news

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 6d

Ontario study of OHIP data (2015–2022): female cancer diagnostic billing dropped in 2020 (cervical −50.7/100k, breast −13.9/100k) but rebounded sharply in 2021–22, with net excesses across all cancer types. COVID-19 disruptions drove delayed diagnoses.

journals.sagepub.com/doi/epdf/10....

1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 6d

Phase III FLINTER trial (N=317) shows rituximab biosimilar DRL_RI is equivalent to MabThera® in untreated low–tumor-burden follicular lymphoma: BORR 80.2% vs 79.4% (Δ0.9%, CI within ±17%). Safety, immunogenicity, PK/PD profiles comparable. #Lymphoma

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 6d

Study of 2896 early-stage #BreastCancer pts: CanAssist Breast prognostic test stratified ER1–20% subgroup. 65% classified low risk with 91% DRFI, 35% high risk with 61% DRFI. CAB may guide tailored therapy beyond ER levels in this challenging group.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 6d

Propensity-matched study (n=127) in extensive-stage #SCLC after first-line chemoimmunotherapy: prophylactic cranial irradiation (PCI) did not improve OS overall but reduced brain metastases (1-yr 13.8% vs 53.4%). OS benefit seen in partial responders.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 6d

Systematic review & network meta-analysis in advanced EGFR-mutated #NSCLC after TKI failure: chemo+ivonescimab ranked best for PFS with acceptable safety; chemo+amivantamab gave strongest OS/ORR but higher toxicity. Chemo+IO or chemo alone less effective.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 13d

Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity.

journals.sagepub.com/doi/epdf/10....

1 1 2

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 13d

Multicenter Mexican cohort (n=477) of young women with #BreastCancer (≤40 yrs): 62% followed a poor long-term QoL trajectory over 5 yrs, with declines in sexual health & future perspective. HER2+ status & public insurance linked to better QoL outcomes.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 13d

Retrospective study of 110 high-risk rectal cancer pts: total neoadjuvant therapy achieved organ preservation in ~50% with 3-yr DFS 75.7% OS 92.4%. Watch & wait strategy gave superior outcomes vs non-pCR pts. TNT supports durable survival & bowel function

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 13d

Study in advanced #GastricCancer: flow cytometry of peritoneal lavage showed CD44+/CD326+ tumor cells correlate with response to repeated intraperitoneal perfusion chemotherapy (RIPPENC). Lower levels linked to resection eligibility & longer survival.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21d

Phase Ib study of xevinapant + avelumab in advanced solid tumours & #NSCLC: RP2D established at 200 mg/day, safety manageable. In NSCLC (n=38), ORR 10.5% (not superior to avelumab alone). Biomarker analyses highlight immune signatures tied to response

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21d

Systematic review & meta-analysis (9 RCTs) in advanced gastric cancer: #immunotherapy + chemo did not improve OS/PFS vs chemo alone in pts with low PD-L1 (CPS<1 or <5). Dual antibody regimens showed PFS benefit (HR 0.64), warranting further study.

Read: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 21d

Retrospective study of 213 late-stage cancer pts in Jordan evaluates #NGS. Clinically significant alterations in 42% (KRAS, PIK3CA, ERBB2, EGFR, BRCA). PFS markedly improved with NGS-guided therapy (HR 0.216) though cost & drug access remain major barriers
journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Aug 5

Thanks to Franziska Geissler, Ksenija Nesic, Olga Kondrashova, Matthew J. Wakefield & co-authors for this in‑depth review on the clinical relevance and pitfalls of assessing DNA methylation in cancer.
#CancerEpigenetics #Oncology

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Aug 5

#TopReadTuesday from TAM:

Aberrant DNA methylation is a hallmark of cancer, driving initiation, progression & therapy resistance.
This review details clinical impacts from MMR gene silencing to BRCA1 methylation loss under treatment pressure.

🔗 journals.sagepub.com/doi/epdf/10....

The role of aberrant DNA methylation in cancer initiation and clinical impacts

journals.sagepub.com

1 1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 16

In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved.

These findings support a synergistic role for RT with immunotherapy.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 16

In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo).
FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 13

New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165):
🔹 Similar MMR at 12 mo (85.1% vs 88.2%)
🔹 Nilotinib led to higher MR4 at all timepoints
🔹 Flumatinib had fewer metabolic/liver AEs

🔗 journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 9

In mRCC, second-line ICI vs TKI showed similar OS (44.8 vs 41.1 mo; p=0.446). But in NLR-high patients, TKI→ICI led to better survival vs TKI→TKI. Bone mets and nephrectomy history also influenced outcomes.
👉 NLR may guide 2L therapy:

doi.org/10.1177/1758...

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 9

In a cohort of 514 cancers, high ICOS expression (14%) was linked to elevated PD-1, PD-L1 & CTLA-4 RNA (all p<0.05) but not survival in ICI-treated or immunotherapy-naïve patients. Suggests ICOS ≠ prognostic, but may guide combo ICI strategies.

doi.org/10.1177/1758...

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 9

📌 In a Chinese LCNEC cohort (n=151), median OS was 17.8 mo. Adjuvant chemo post-surgery reduced distant spread & improved 2-yr OS (37.1% vs 79.9%, p<0.001). Immunochemotherapy outperformed chemo alone in advanced disease.

doi.org/10.1177/1758...

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · May 9

📊 In non-resectable stage III melanoma, T-VEC and IL-2 showed no significant differences in PFS (5.0 mo), OS (34.0 mo), or response rates. Both were well tolerated with minimal AEs. Real-world data to guide intralesional therapy choice.

doi.org/10.1177/1758...

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Apr 16

3 patients with metastatic KRAS-wildtype PDAC showed prolonged response to osimertinib after EGFR exon 19 deletion was found via NGS. Early molecular & metabolic responses seen; disease controlled for 6, 8, and 17 months. A case for rare mutation testing

journals.sagepub.com/doi/epdf/10....

1 2

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Apr 16

First reported case of coma from luminal breast cancer brain mets reversed without radiation: patient treated w/ nasogastric abemaciclib + fulvestrant post-surgery. Seizures resolved, imaging improved, full functional recovery—patient returned to work

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Apr 15

Thanks to Landon L. Chan and Stephen L. Chan for this expert look at the evolving future of immunotherapy in hepatocellular carcinoma.

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · Apr 15

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications.

Read here: journals.sagepub.com/doi/epdf/10....

1 1 1